<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35866369</PMID><DateCompleted><Year>2022</Year><Month>10</Month><Day>27</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>23</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1938-3673</ISSN><JournalIssue CitedMedium="Internet"><Volume>112</Volume><Issue>5</Issue><PubDate><Year>2022</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Journal of leukocyte biology</Title><ISOAbbreviation>J Leukoc Biol</ISOAbbreviation></Journal><ArticleTitle>Single-cell immune profiling reveals long-term changes in myeloid cells and identifies a novel subset of CD9<sup>+</sup> monocytes associated with COVID-19 hospitalization.</ArticleTitle><Pagination><StartPage>1053</StartPage><EndPage>1063</EndPage><MedlinePgn>1053-1063</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/JLB.4COVA0122-076R</ELocationID><Abstract><AbstractText>Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection can result in severe immune dysfunction, hospitalization, and death. Many patients also develop long-COVID-19, experiencing symptoms months after infection. Although significant progress has been made in understanding the immune response to acute SARS-CoV-2 infection, gaps remain in our knowledge of how innate immunity influences disease kinetics and severity. We hypothesized that cytometry by time-of-flight analysis of PBMCs from healthy and infected subjects would identify novel cell surface markers and innate immune cell subsets associated with COVID-19 severity. In this pursuit, we identified monocyte and dendritic cell subsets that changed in frequency during acute SARS-CoV-2 infection and correlated with clinical parameters of disease severity. Subsets of nonclassical monocytes decreased in frequency in hospitalized subjects, yet increased in the most severe patients and positively correlated with clinical values associated with worse disease severity. CD9, CD163, PDL1, and PDL2 expression significantly increased in hospitalized subjects, and CD9 and 6-Sulfo LacNac emerged as the markers that best distinguished monocyte subsets amongst all subjects. CD9<sup>+</sup> monocytes remained elevated, whereas nonclassical monocytes remained decreased, in the blood of hospitalized subjects at 3-4 months postinfection. Finally, we found that CD9<sup>+</sup> monocytes functionally released more IL-8 and MCP-1 after LPS stimulation. This study identifies new monocyte subsets present in the blood of COVID-19 patients that correlate with disease severity, and links CD9<sup>+</sup> monocytes to COVID-19 progression.</AbstractText><CopyrightInformation>&#xa9;2022 Society for Leukocyte Biology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pandori</LastName><ForeName>William J</ForeName><Initials>WJ</Initials><AffiliationInfo><Affiliation>Center for Autoimmunity and Inflammation, La Jolla Institute for Immunology, La Jolla, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Padgett</LastName><ForeName>Lindsey E</ForeName><Initials>LE</Initials><AffiliationInfo><Affiliation>Center for Autoimmunity and Inflammation, La Jolla Institute for Immunology, La Jolla, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alimadadi</LastName><ForeName>Ahmad</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Center for Autoimmunity and Inflammation, La Jolla Institute for Immunology, La Jolla, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gutierrez</LastName><ForeName>Norma A</ForeName><Initials>NA</Initials><AffiliationInfo><Affiliation>Center for Autoimmunity and Inflammation, La Jolla Institute for Immunology, La Jolla, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Araujo</LastName><ForeName>Daniel J</ForeName><Initials>DJ</Initials><AffiliationInfo><Affiliation>Center for Autoimmunity and Inflammation, La Jolla Institute for Immunology, La Jolla, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huh</LastName><ForeName>Christine J</ForeName><Initials>CJ</Initials><AffiliationInfo><Affiliation>Center for Autoimmunity and Inflammation, La Jolla Institute for Immunology, La Jolla, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Olingy</LastName><ForeName>Claire E</ForeName><Initials>CE</Initials><AffiliationInfo><Affiliation>Center for Autoimmunity and Inflammation, La Jolla Institute for Immunology, La Jolla, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dinh</LastName><ForeName>Huy Q</ForeName><Initials>HQ</Initials><AffiliationInfo><Affiliation>Center for Autoimmunity and Inflammation, La Jolla Institute for Immunology, La Jolla, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Runpei</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Center for Autoimmunity and Inflammation, La Jolla Institute for Immunology, La Jolla, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vijayanand</LastName><ForeName>Pandurangan</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Center for Autoimmunity and Inflammation, La Jolla Institute for Immunology, La Jolla, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chee</LastName><ForeName>Serena J</ForeName><Initials>SJ</Initials><AffiliationInfo><Affiliation>Institute of Systems, Molecular and Integrative Biology (ISMIB), University of Liverpool, Liverpool, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ottensmeier</LastName><ForeName>Christian H</ForeName><Initials>CH</Initials><AffiliationInfo><Affiliation>Center for Autoimmunity and Inflammation, La Jolla Institute for Immunology, La Jolla, California, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Systems, Molecular and Integrative Biology (ISMIB), University of Liverpool, Liverpool, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hedrick</LastName><ForeName>Catherine C</ForeName><Initials>CC</Initials><AffiliationInfo><Affiliation>Center for Autoimmunity and Inflammation, La Jolla Institute for Immunology, La Jolla, California, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>F32 HL146069</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 HL136275</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>S10 OD018499</GrantID><Acronym>OD</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 AI125179</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>07</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Leukoc Biol</MedlineTA><NlmUniqueID>8405628</NlmUniqueID><ISSNLinking>0741-5400</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016209">Interleukin-8</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008070">Lipopolysaccharides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C554869">CD9 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D060245">Tetraspanin 29</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009000" MajorTopicYN="N">Monocytes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016209" MajorTopicYN="N">Interleukin-8</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008070" MajorTopicYN="N">Lipopolysaccharides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D022423" MajorTopicYN="N">Myeloid Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="N">Hospitalization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D060245" MajorTopicYN="N">Tetraspanin 29</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">CyTOF</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">Slan</Keyword><Keyword MajorTopicYN="N">T cells</Keyword><Keyword MajorTopicYN="N">long-COVID-19</Keyword><Keyword MajorTopicYN="N">nonclassical monocytes</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>3</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>2</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>5</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>7</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>10</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>7</Month><Day>22</Day><Hour>4</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>7</Month><Day>22</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35866369</ArticleId><ArticleId IdType="pmc">PMC9350203</ArticleId><ArticleId IdType="doi">10.1002/JLB.4COVA0122-076R</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Dong E, Du H, Gardner L. An interactive web&#x2010;based dashboard to track COVID&#x2010;19 in real time. Lancet. 2020;20:533&#x2010;534.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7159018</ArticleId><ArticleId IdType="pubmed">32087114</ArticleId></ArticleIdList></Reference><Reference><Citation>Guan WJ, Ni ZY, Hu Y, et&#xa0;al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382:1708&#x2010;1720.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7092819</ArticleId><ArticleId IdType="pubmed">32109013</ArticleId></ArticleIdList></Reference><Reference><Citation>Ren X, Wen W, Fan X, et&#xa0;al. COVID&#x2010;19 immune features revealed by a large&#x2010;scale single&#x2010;cell transcriptome atlas. Cell. 2021;184:1895&#x2010;1913.e19.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7857060</ArticleId><ArticleId IdType="pubmed">33657410</ArticleId></ArticleIdList></Reference><Reference><Citation>Arunachalam PS, Wimmers F, Mok CKP, et&#xa0;al. Systems biological assessment of immunity to mild versus severe COVID&#x2010;19 infection in humans. Science (80&#x2010;). 2020;369:1210&#x2010;1220.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7665312</ArticleId><ArticleId IdType="pubmed">32788292</ArticleId></ArticleIdList></Reference><Reference><Citation>Laing AG, Lorenc A, del Molino del Barrio I, et&#xa0;al. A dynamic COVID&#x2010;19 immune signature includes associations with poor prognosis. Nat Med. 2020;26:1623&#x2010;1635.</Citation><ArticleIdList><ArticleId IdType="pubmed">32807934</ArticleId></ArticleIdList></Reference><Reference><Citation>Schulte&#x2010;Schrepping J, Reusch N, Paclik D, et&#xa0;al. Severe COVID&#x2010;19 is marked by a dysregulated myeloid cell compartment. Cell. 2020;182:1419&#x2010;1440.e23.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7405822</ArticleId><ArticleId IdType="pubmed">32810438</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu C, Martins AJ, Lau WW, et&#xa0;al. Time&#x2010;resolved systems immunology reveals a late juncture linked to fatal COVID&#x2010;19. Cell. 2021;184:1836&#x2010;1857 e22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7874909</ArticleId><ArticleId IdType="pubmed">33713619</ArticleId></ArticleIdList></Reference><Reference><Citation>Gibellini L, De Biasi S, Paolini A, et&#xa0;al. Altered bioenergetics and mitochondrial dysfunction of monocytes in patients with COVID&#x2010;19 pneumonia. EMBO Mol Med 12. 10.15252/emmm.202013001. Epub ahead of print December 7, 2020.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/emmm.202013001</ArticleId><ArticleId IdType="pmc">PMC7645870</ArticleId><ArticleId IdType="pubmed">33078545</ArticleId></ArticleIdList></Reference><Reference><Citation>Giamarellos&#x2010;Bourboulis EJ, Netea MG, Rovina N, et&#xa0;al. Complex immune dysregulation in COVID&#x2010;19 patients with severe respiratory failure. Cell Host Microbe. 2020;27:992&#x2010;1000 e3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7172841</ArticleId><ArticleId IdType="pubmed">32320677</ArticleId></ArticleIdList></Reference><Reference><Citation>Szabo PA, Dogra P, Gray JI, et&#xa0;al. Longitudinal profiling of respiratory and systemic immune responses reveals myeloid cell&#x2010;driven lung inflammation in severe COVID&#x2010;19. Immunity. 2021;54:797&#x2010;814.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7951561</ArticleId><ArticleId IdType="pubmed">33765436</ArticleId></ArticleIdList></Reference><Reference><Citation>Gatti A, Radrizzani D, Vigano P, et&#xa0;al. Decrease of non&#x2010;classical and intermediate monocyte subsets in severe acute SARS&#x2010;CoV&#x2010;2 infection. Cytom A. 2020;97:887&#x2010;890.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7404377</ArticleId><ArticleId IdType="pubmed">32654350</ArticleId></ArticleIdList></Reference><Reference><Citation>Silvin A, Chapuis N, Dunsmore G, et&#xa0;al. Elevated calprotectin and abnormal myeloid cell subsets discriminate severe from mild COVID&#x2010;19. Cell. 2020;182:1401&#x2010;1418.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7405878</ArticleId><ArticleId IdType="pubmed">32810439</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanchez&#x2010;Cerrillo I, Landete P, Aldave B, et&#xa0;al. COVID&#x2010;19 severity associates with pulmonary redistribution of CD1c+ DC and inflammatory transitional and nonclassical monocytes. J Clin Invest. 2020;130:6290&#x2010;6300.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7685723</ArticleId><ArticleId IdType="pubmed">32784290</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomas GD, Hamers AAJ, Nakao C, et&#xa0;al. Human blood monocyte subsets: a new gating strategy defined using cell surface markers identified by mass cytometry. Arter Thromb Vasc Biol. 2017;37:1548&#x2010;1558.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5828170</ArticleId><ArticleId IdType="pubmed">28596372</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamers AAJ, Dinh HQ, Thomas GD, et&#xa0;al. Human monocyte heterogeneity as revealed by high&#x2010;dimensional mass cytometry. Arterioscler Thromb Vasc Biol. 2019;39:25&#x2010;36.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6697379</ArticleId><ArticleId IdType="pubmed">30580568</ArticleId></ArticleIdList></Reference><Reference><Citation>Krychtiuk KA, Lenz M, Richter B, et&#xa0;al. Monocyte subsets predict mortality after cardiac arrest. J Leukoc Biol. 2021;109:1139&#x2010;1146.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8247267</ArticleId><ArticleId IdType="pubmed">33020969</ArticleId></ArticleIdList></Reference><Reference><Citation>Combes AJ, Courau T, Kuhn NF, et&#xa0;al. Global absence and targeting of protective immune states in severe COVID&#x2010;19. Nature. 2021;591:124&#x2010;130.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8567458</ArticleId><ArticleId IdType="pubmed">33494096</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Wijst MGP, Vazquez SE, Hartoularos GC, et&#xa0;al. Type I interferon autoantibodies are associated with systemic immune alterations in patients with COVID&#x2010;19. Sci Transl Med. 2021;13. 10.1126/scitranslmed.abh2624. Epub ahead of print.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.abh2624</ArticleId><ArticleId IdType="pmc">PMC8601717</ArticleId><ArticleId IdType="pubmed">34429372</ArticleId></ArticleIdList></Reference><Reference><Citation>Meckiff BJ, Ramirez&#x2010;Suastegui C, Fajardo V, et&#xa0;al. Imbalance of regulatory and cytotoxic SARS&#x2010;CoV&#x2010;2&#x2010;reactive CD4+ T cells in COVID&#x2010;19. Cell. 2020;183:1340&#x2010;1353.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7534589</ArticleId><ArticleId IdType="pubmed">33096020</ArticleId></ArticleIdList></Reference><Reference><Citation>Kusnadi A, Ramirez&#x2010;Suastegui C, Fajardo V, et&#xa0;al. Severely ill COVID&#x2010;19 patients display augmented functional properties in SARS&#x2010;CoV&#x2010;2&#x2010;reactive CD8+ T cells. Sci Immunol. 6. 10.1126/sciimmunol.abe4782. Epub ahead of print 2021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciimmunol.abe4782</ArticleId><ArticleId IdType="pmc">PMC8101257</ArticleId><ArticleId IdType="pubmed">33478949</ArticleId></ArticleIdList></Reference><Reference><Citation>Zunder ER, Finck R, Behbehani GK, et&#xa0;al. Palladium&#x2010;based mass tag cell barcoding with a doublet&#x2010;filtering scheme and single&#x2010;cell deconvolution algorithm. Nat Protoc. 2015;10:316&#x2010;333.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4347881</ArticleId><ArticleId IdType="pubmed">25612231</ArticleId></ArticleIdList></Reference><Reference><Citation>Lun ATL, Richard AC, Marioni JC. Testing for differential abundance in mass cytometry data. Nat Methods. 2017;14:707&#x2010;709.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6155493</ArticleId><ArticleId IdType="pubmed">28504682</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Gassen S, Callebaut B, Van Helden MJ, et&#xa0;al. FlowSOM: using self&#x2010;organizing maps for visualization and interpretation of cytometry data. Cytom A. 2015;87:636&#x2010;645.</Citation><ArticleIdList><ArticleId IdType="pubmed">25573116</ArticleId></ArticleIdList></Reference><Reference><Citation>Ritchie ME, Phipson B, Wu D, et&#xa0;al. Limma powers differential expression analyses for RNA&#x2010;sequencing and microarray studies. Nucleic Acids Res. 2015;43:e47.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4402510</ArticleId><ArticleId IdType="pubmed">25605792</ArticleId></ArticleIdList></Reference><Reference><Citation>Bates D, M&#xe4;chler M, Bolker BM, et&#xa0;al. Fitting linear mixed&#x2010;effects models using lme4. 10.18637/jss.v067.i01. Epub ahead of print October 1, 2015.</Citation><ArticleIdList><ArticleId IdType="doi">10.18637/jss.v067.i01</ArticleId></ArticleIdList></Reference><Reference><Citation>Freeman BGJ, Long AJ, Iwai Y, et&#xa0;al. Engagement of the PD&#x2010;1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med. 2000;192:1028&#x2010;1034.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2193311</ArticleId><ArticleId IdType="pubmed">11015443</ArticleId></ArticleIdList></Reference><Reference><Citation>Latchman Y, Wood CR, Chernova T, et&#xa0;al. PD&#x2010;L2 is a second ligand for PD&#x2010;1 and inhibits T cell activation. Nat Immunol. 2001;2:261&#x2010;268.</Citation><ArticleIdList><ArticleId IdType="pubmed">11224527</ArticleId></ArticleIdList></Reference><Reference><Citation>Brosseau C, Colas L, Magnan A, et&#xa0;al. CD9 tetraspanin: a new pathway for the regulation of inflammation?. Front Immunol. 2018;9:2316. 10.3389/fimmu.2018.02316. Epub ahead of print October 9.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2018.02316</ArticleId><ArticleId IdType="pmc">PMC6189363</ArticleId><ArticleId IdType="pubmed">30356731</ArticleId></ArticleIdList></Reference><Reference><Citation>Suzuki M, Tachibana I, Takeda Y, et&#xa0;al. Tetraspanin CD9 negatively regulates lipopolysaccharide&#x2010;induced macrophage activation and lung inflammation. J Immunol. 2009;182:6485&#x2010;6493.</Citation><ArticleIdList><ArticleId IdType="pubmed">19414803</ArticleId></ArticleIdList></Reference><Reference><Citation>Rocha&#x2010;Perugini V, Martinez Del Hoyo G, Gonzalez&#x2010;Granado JM, et&#xa0;al. CD9 regulates major histocompatibility complex class II trafficking in monocyte&#x2010;derived dendritic cells. Mol Cell Biol. 2017;37. 10.1128/MCB.00202-17. Epub ahead of print.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/MCB.00202-17</ArticleId><ArticleId IdType="pmc">PMC5514457</ArticleId><ArticleId IdType="pubmed">28533221</ArticleId></ArticleIdList></Reference><Reference><Citation>Rocha&#x2010;Perugini V, Gonz&#xe1;lez&#x2010;Granado JM, Tejera E, et&#xa0;al. Tetraspanins CD9 and CD151 at the immune synapse support T&#x2010;cell integrin signaling. Eur J Immunol. 2014;44:1967&#x2010;1975.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4630866</ArticleId><ArticleId IdType="pubmed">24723389</ArticleId></ArticleIdList></Reference><Reference><Citation>Kischel P, Bellahcene A, Deux B, et&#xa0;al. Overexpression of CD9 in human breast cancer cells promotes the development of bone metastases. Anticancer Res. 2012;32:5211&#x2010;5220.</Citation><ArticleIdList><ArticleId IdType="pubmed">23225418</ArticleId></ArticleIdList></Reference><Reference><Citation>Mann ER, Immunol S, Mann ER, et&#xa0;al. Longitudinal immune profiling reveals key myeloid signatures associated with COVID&#x2010;19. Sci Immunol 5. Epub ahead of print 2020. 10.1126/sciimmunol.abd6197</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciimmunol.abd6197</ArticleId><ArticleId IdType="pmc">PMC7857390</ArticleId><ArticleId IdType="pubmed">32943497</ArticleId></ArticleIdList></Reference><Reference><Citation>Saris A, Reijnders TDY, Reijm M, et&#xa0;al. Enrichment of CCR6+CD8+ T cells and CCL20 in the lungs of mechanically ventilated patients with COVID&#x2010;19. Eur J Immunol. 2021: 1535&#x2010;1538.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8250259</ArticleId><ArticleId IdType="pubmed">33768543</ArticleId></ArticleIdList></Reference><Reference><Citation>Dengel LT, Norrod AG, Gregory BL, et&#xa0;al. Interferons induce CXCR3&#x2010;cognate chemokine production by human metastatic melanoma. J Immunother. 2010;33:965&#x2010;974.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3110268</ArticleId><ArticleId IdType="pubmed">20948440</ArticleId></ArticleIdList></Reference><Reference><Citation>Loetscher M, Gerber B, Loetscher P, et&#xa0;al. Chemokine receptor specific for IP10 and Mig: structure, function, and expression in activate T&#x2010;Lymphocytes. J Exp Med. 1996;184:963&#x2010;969.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2192763</ArticleId><ArticleId IdType="pubmed">9064356</ArticleId></ArticleIdList></Reference><Reference><Citation>Hadjadj J, Yatim N, Barnabei L, et&#xa0;al. Impaired type I interferon activity and inflammatory responses in severe COVID&#x2010;19 patients. Science (80&#x2010;). 2020;369:718&#x2010;724.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7402632</ArticleId><ArticleId IdType="pubmed">32661059</ArticleId></ArticleIdList></Reference><Reference><Citation>Sudre CH, Murray B, Varsavsky T, et&#xa0;al. Attributes and predictors of long COVID. Nat Med. 2021;27:626&#x2010;631.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7611399</ArticleId><ArticleId IdType="pubmed">33692530</ArticleId></ArticleIdList></Reference><Reference><Citation>Nalbandian A, Sehgal K, Gupta A, et&#xa0;al. Post&#x2010;acute COVID&#x2010;19 syndrome. Nat Med. 2021;27:601&#x2010;615.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8893149</ArticleId><ArticleId IdType="pubmed">33753937</ArticleId></ArticleIdList></Reference><Reference><Citation>Carfi A, Bernabei R, Landi F, et&#xa0;al. Persistent symptoms in patients after acute COVID&#x2010;19. JAMA. 2020;324:603&#x2010;605.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7349096</ArticleId><ArticleId IdType="pubmed">32644129</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>